Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James C Yao
SWOG Cancer Research Network
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
494 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Providence Hospital
Mobile, Alabama, United States
- Fairbanks Memorial Hospital
Fairbanks, Alaska, United States
- Mercy Hospital Fort Smith
Fort Smith, Arkansas, United States
- Nea Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas, United States
- University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
- Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
- Kaiser Permanente-Anaheim
Anaheim, California, United States
- Arroyo Grande Community
Arroyo Grande, California, United States
- Pcr Oncology
Arroyo Grande, California, United States
- Kaiser Permanente-Baldwin Park
Baldwin Park, California, United States
- Kaiser Permanente-Bellflower
Bellflower, California, United States
- Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
- Providence Saint Joseph Medical Center/disney Family Cancer Center
Burbank, California, United States
- Mills-Peninsula Medical Center
Burlingame, California, United States
- Kaiser Permanente-Fontana
Fontana, California, United States
- Marin General Hospital
Greenbrae, California, United States
- Kaiser Permanente South Bay
Harbor City, California, United States
- Kaiser Permanente-Irvine
Irvine, California, United States
- Cedars-Sinai Medical Center
Los Angeles, California, United States
- Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
- Kaiser Permanente West Los Angeles
Los Angeles, California, United States
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Sutter Cancer Research Consortium
Novato, California, United States
- Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
- Kaiser Permanente - Panorama City
Panorama City, California, United States
- Kaiser Permanente-Riverside
Riverside, California, United States
- Kaiser Permanente-San Diego Mission
San Diego, California, United States
- Kaiser Permanente-San Diego Zion
San Diego, California, United States
- California Pacific Medical Center-Pacific Campus
San Francisco, California, United States
- Kaiser Permanente-San Marcos
San Marcos, California, United States
- Sutter Pacific Medical Foundation
Santa Rosa, California, United States
- Sutter Solano Medical Center/cancer Center
Vallejo, California, United States
- Kaiser Permanente-Woodland Hills
Woodland Hills, California, United States
- San Luis Valley Regional Medical Center
Alamosa, Colorado, United States
- Rocky Mountain Regional Va Medical Center
Aurora, Colorado, United States
- the Medical Center of Aurora
Aurora, Colorado, United States
- Uchealth University of Colorado Hospital
Aurora, Colorado, United States
- Boulder Community Foothills Hospital
Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Dec 2007
- Primary completion
- 1 Jan 2015
- Completion
- 31 Jan 2027
- Last update posted
- 29 May 2026
- Registered enrollment
- 427
- Registry id
- NCT00569127
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.